(-0.05%) 5 476.00 points
(-0.07%) 38 791 points
(-0.02%) 19 918 points
(0.29%) $80.56
(1.18%) $2.82
(0.24%) $2 334.60
(-0.17%) $29.34
(-0.21%) $968.90
(0.01%) $0.932
(-0.15%) $10.64
(0.05%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa...
Stats | |
---|---|
Šios dienos apimtis | 324 263 |
Vidutinė apimtis | 725 173 |
Rinkos kapitalizacija | 184.74M |
EPS | $-1.160 ( Q1 | 2024-05-15 ) |
Kita pelno data | ( $-0.290 ) 2024-08-13 |
Last Dividend | $3 706.25 ( 2000-03-31 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.430 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0100 (0.22%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-05 | Vazzano Joseph Walter | Sell | 16 408 | Common stock |
2024-06-05 | Seshadri Vishwas | Sell | 38 621 | Common Stock |
2024-06-05 | O'malley Brendan M. | Sell | 10 951 | Common stock |
2024-03-31 | O'malley Brendan M. | Sell | 92 | Common stock |
2024-06-03 | Seshadri Vishwas | Sell | 703 | Common Stock |
INSIDER POWER |
---|
93.41 |
Last 97 transactions |
Buy: 7 563 115 | Sell: 596 202 |
Tūris Koreliacija
Abeona Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
OZEM | 1 |
NBBK | 0.952 |
MAMA | 0.946 |
EVCGX | 0.934 |
BUJA | 0.919 |
MMUKX | 0.918 |
PRE | 0.915 |
HUMA | 0.914 |
MICFX | 0.912 |
MCHFX | 0.912 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
IIMFX | -0.942 |
INDH | -0.917 |
NWGL | -0.89 |
QREARX | -0.89 |
HTOOW | -0.885 |
IVP | -0.881 |
AONC | -0.877 |
OPTZ | -0.875 |
BAER | -0.874 |
APLM | -0.873 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Abeona Therapeutics Inc Koreliacija - Valiuta/Žaliavos
Abeona Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $3.50M |
Bruto pelnas: | $302 000 (8.63 %) |
EPS: | $-2.53 |
FY | 2023 |
Pajamos: | $3.50M |
Bruto pelnas: | $302 000 (8.63 %) |
EPS: | $-2.53 |
FY | 2022 |
Pajamos: | $1.41M |
Bruto pelnas: | $964 000 (68.18 %) |
EPS: | $-4.05 |
FY | 2021 |
Pajamos: | $3.00M |
Bruto pelnas: | $3.00M (100.00 %) |
EPS: | $-21.57 |
Financial Reports:
No articles found.
Abeona Therapeutics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $3 706.25 | 2000-03-31 |
Last Dividend | $3 706.25 | 2000-03-31 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $3 706.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2000 | $3.00 | 0.03% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
31 Mar 2000 | $3 706.25 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -12.12 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.024 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -8.21 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.61 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.46 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.505 | 1.500 | 2.75 | 4.12 | [0.2 - 2] |
debtRatioTTM | 0.256 | -1.500 | 5.74 | -8.61 | [0 - 0.6] |
interestCoverageTTM | -39.79 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.457 | 2.00 | -0.486 | -0.971 | [0 - 30] |
freeCashFlowPerShareTTM | -1.488 | 2.00 | -0.744 | -1.488 | [0 - 20] |
debtEquityRatioTTM | -2.15 | -1.500 | -8.61 | 10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.520 | 1.000 | 4.66 | 4.66 | [0.2 - 0.8] |
operatingProfitMarginTTM | -7.98 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -2.08 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0845 | 0.800 | -2.77 | -2.22 | [0.5 - 2] |
Total Score | -4.38 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.586 | 1.000 | -0.261 | 0 | [1 - 100] |
returnOnEquityTTM | -8.21 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.488 | 2.00 | -0.496 | -1.488 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.457 | 2.00 | -0.486 | -0.971 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0165 | 1.500 | -3.44 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -6.29 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.74 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.